Treatments, Simulants, and Screening
Learning Objectives
- Separate treatment, simulant identification, and natural/laboratory-grown screening as different questions.
- Require treatment disclosure to remain consistent across listing, report, invoice, and future service records.
- Apply screening only within validated scope and distinguish
OUT-OF-RANGEdevice output from anOUT OF SCOPEapplicability boundary.
Core
A treatment can alter color, clarity, or appearance. Treatment status is not a minor footnote: it can affect product identity, disclosure, care, service, documentation, and market comparison.
A simulant is not diamond material. A laboratory-grown diamond is diamond with a different growth origin. A treated natural diamond is natural diamond whose properties have been altered. These are three different categories of problem.
A handheld tester that separates some materials may not resolve origin or treatment. Screening begins by defining the question the method is supposed to answer.
Apply
Buyer’s Guide 08 — Treatments and Disclosure
Red flags
- “Enhanced” is used without a precise explanation.
- Treatment is disclosed only after repeated questioning.
- The invoice omits a material disclosure made during the sale.
- “Permanent” is used as though it means no special care or service limitation exists.
- Treated and untreated stones are compared on price without equivalent disclosure.
- A workshop receives no treatment information before intervention.
Purchase checklist
- Treatment status is clear before payment.
- Listing, report, and invoice are consistent.
- Any special cleaning or service risk is understood.
- Natural/laboratory-grown origin is kept separate from treatment or color-origin questions.
- Price comparisons use compatibly documented products.
- Treatment records are retained for future service and resale.
Fracture filling and coating require particular caution because service/report eligibility and care can differ from an untreated stone. Do not generalize all treatment cases into one disclosure or service rule.
Buyer’s Guide 09 — Simulants, Screening, and Digital Fraud
Red flags
- One home test is presented as final identification.
- “Passes a diamond tester” is used as proof of natural origin.
- The seller supplies only a screenshot of report verification.
- A real report number exists, but measurements do not match the stone or listing.
- Payment removes reasonable dispute or return protection.
- The seller refuses independent verification for a high-value transaction.
Purchase checklist
- I know whether the unresolved problem is material/simulant, origin, or treatment.
- I know the validated scope of the tester or screening device.
- The official record is checked independently.
- The report is connected to the physical stone through an actual matching plan.
- Seller identity and payment/delivery workflow are verifiable.
- A high-risk case has an independent gemological or laboratory escalation path.
For screening terminology, keep two concepts separate. OUT-OF-RANGE is a device-result label where defined by that device. OUT OF SCOPE describes a validation/applicability boundary and is not the same result. A REFER or OUT-OF-RANGE result follows the device’s defined escalation pathway; an OUT OF SCOPE case requires a method validated for that use case.
Check Your Understanding
- What is the exact treatment status, and is disclosure consistent across the transaction documents?
- Is there a care or workshop consequence that must be preserved with the stone’s records?
- What exact question can the tester or device answer?
- Am I keeping
OUT-OF-RANGEseparate fromOUT OF SCOPE? - Is the seller’s digital identity separate from report authenticity and physical-stone matching?
- What result or uncertainty would require laboratory escalation?
Conclusion Boundary
Stop or escalate when treatment status is unclear, disclosure is inconsistent, service safety is uncertain, or the selected identification/screening method cannot answer the actual question. Treat REFER and OUT-OF-RANGE according to the device workflow; treat OUT OF SCOPE as a validation boundary requiring a different appropriately validated method. Digital records never replace physical matching.
Common Mistakes
“Permanent treatment means service is always routine.”
No.
“Laboratory-grown is a simulant.”
No.
“A diamond-tester pass proves natural origin.”
No.
“OUT-OF-RANGE and OUT OF SCOPE are synonyms.”
No.
Remember
First classify the problem: treatment + material + origin + device scope + document authenticity + physical match are separate decision layers.
Sources
- Buyer’s Guide: HOK-DIA-BUYERS-GUIDE-CH-008
- Buyer’s Guide: HOK-DIA-BUYERS-GUIDE-CH-009
- Handbook:
HOK-DIA-HANDBOOK-CH-020 - Handbook:
HOK-DIA-HANDBOOK-CH-021 - Handbook:
HOK-DIA-HANDBOOK-CH-023 - The Book:
HOK-DIA-BOOK-CH-057 - The Book:
HOK-DIA-BOOK-CH-058 - The Book:
HOK-DIA-BOOK-CH-059 - The Book:
HOK-DIA-BOOK-CH-060 - The Book:
HOK-DIA-BOOK-CH-061 - The Book:
HOK-DIA-BOOK-CH-062 - The Book:
HOK-DIA-BOOK-CH-063 - The Book:
HOK-DIA-BOOK-CH-064 - The Book:
HOK-DIA-BOOK-CH-065 - The Book:
HOK-DIA-BOOK-CH-066 - The Book:
HOK-DIA-BOOK-CH-067 - The Book:
HOK-DIA-BOOK-CH-073 - The Book:
HOK-DIA-BOOK-CH-074